Randomized Controlled Trial
Copyright ©The Author(s) 2023.
World J Gastrointest Oncol. May 15, 2023; 15(5): 878-891
Published online May 15, 2023. doi: 10.4251/wjgo.v15.i5.878
Table 4 Overall adenoma detection rate in patients of the subgroup

NBI group (n = 2016)
LCI group (n = 97)
WLI group (n = 2098)
P value1
RR (95%CI)
P value2
RR (95%CI)
P value3
RR (95%CI)
ADR478/2016 (23.7)30/97 (30.9)458/2098 (21.8)0.151.09 (0.97-1.22)0.041.42 (1.04-1.93)0.100.77 (0.56-1.04)
Advanced ADR122/2016 (6.1)5/97 (5.2)116/2098 (5.5)0.471.10 (0.86-1.40)0.870.93 (0.39-2.23)0.721.17 (0.49-2.80)
Diminutive ADR304/2016 (15.1)19/97 (19.6)286/2098 (13.6)0.191.11 (0.95-1.28)0.101.44 (0.95-2.18)0.230.77 (0.51-1.17)
ADR in different ages
< 50 yr55/538 (10.2)12/48 (25.0)54/557 (9.7)0.771.05 (0.74-1.51)0.012.58 (1.49-4.48)0.010.41 (0.24-0.71)
≥ 50 yr423/1478 (28.6)18/49 (36.7)404/1541 (26.2)0.141.09 (0.97-1.23)0.101.40 (0.96-2.04)0.220.78 (0.54-1.14)
ADR in different gender
Male270/953 (28.3)18/49 (36.7)254/982 (25.9)0.221.10 (0.95-1.27)0.091.42 (0.97-2.08)0.210.77 (0.53-1.13)
Female208/1063 (19.6)12/48 (25.0)204/1116 (18.3)0.441.07 (0.90-1.27)0.241.37 (0.83-2.27)0.360.78 (0.47-1.30)
ADR with different indications
Diagnostic
< 50 yr23/247 (9.3)3/23 (13.0)23/256 (9.0)0.901.04 (0.60-1.80)0.4641.45 (0.47-4.47)0.4740.71 (0.23-2.20)
≥ 50 yr171/590 (29.0)8/20 (40.0)166/620 (26.8)0.391.08 (0.90-1.30)0.191.49 (0.86-2.60)0.290.73 (0.42-1.26)
Surveillance
< 50 yr8/96 (8.3)1/8 (12.5)7/93 (7.5)0.841.11 (0.42-2.93)0.5041.66 (0.23-11.87)0.5340.67 (0.10-4.69)
≥ 50 yr134/496 (27.0)4/13 (30.8)126/508 (24.8)0.421.09 (0.88-1.34)0.7541.24 (0.54-2.84)0.7640.88 (0.38-2.01)
Screening
< 50 yr24/195 (12.3)8/17 (47.1)24/208 (11.5)0.811.07 (0.63-1.81)0.014.08 (2.17-7.65)0.0140.26 (0.14-0.49)
≥ 50 yr118/392 (30.1)6/16 (37.5)112/413 (27.1)0.351.11 (0.89-1.38)0.401.38 (0.72-2.65)0.580.80 (0.42-1.54)
Withdrawal time7.90 ± 3.467.82 ± 2.677.85 ± 3.470.470.020.05